FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Julie E. Bauman, Lisa F. Licitra, Bhumsuk Keam, Jessica R. Bauman, Victor T. G. Lin, Neal Akhave, Jérôme Fayette, Prakash C. Neupane, Hussein Soudy, Byoung Chul Cho, Christine H. Chung, Nabil F. Saba, Deborah J.L. Wong, Kevin Joseph Harrington, Christophe Le Tourneau, Suzy Muggeo, Bo Jin, Claudia Lebedinsky, Edgar E. Braendle, Robert I. Haddad
Institutions: Fox Chase Cancer Center, George Washington University, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Seoul National University, Seoul National University Hospital, Mary Bird Perkins Cancer Center, The University of Texas MD Anderson Cancer Center, Centre Léon Bérard, The University of Kansas Cancer Center, University of Kansas Medical Center, St George Hospital, Severance Hospital, Yonsei Cancer Hospital, Moffitt Cancer Center, Winship Cancer Institute, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Institut Curie, AVEO Oncology (United States), Dana-Farber Cancer Institute
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410810896